Variant Synonymizer: Platform to identify mutations defined in different ways is available now!
Over 2,000 gene–disease validation summaries are now available—no login required!
Long chain acyl-CoA dehydrogenase deficiency is an autosomal recessive fatty acid oxidation disorder characterized by hypoglycemia, muscle weakness, and respiratory failure. Biallelic variants in ACADL disrupt mitochondrial fatty acid β-oxidation.
Evidence includes 12 unrelated probands (PMID:1945557; PMID:1424161; PMID:18283146) demonstrating enzyme deficiency and compatible clinical phenotypes. No multigenerational segregation data are available.
Immunochemical analysis of LCAD in fibroblasts from nine patients reveals a single variant band of normal size but reduced catalytic activity, consistent with point mutations causing stable but functionally impaired enzyme (PMID:1945557). Assays using purified electron transfer flavoprotein quantify decreased dehydrogenase activity in two additional patients (PMID:1424161).
In a murine model, rAAV-mediated delivery of the mLCAD transgene restores mitochondrial LCAD levels and reduces lipid accumulation in muscle and liver of LCAD+/– mice, supporting haploinsufficiency and demonstrating in vivo rescue (PMID:18720429).
Conflicting data arise from initial identification of LCAD deficiency in three patients by reduced palmitoyl-CoA activity; PCR and sequencing in two cases showed normal ACADL, and VLCAD immunoblotting implicated misdiagnosis due to VLCAD deficiency (PMID:8356011).
Collectively, this strong gene–disease association is supported by robust genetic and biochemical evidence. Molecular testing for ACADL is critical for accurate diagnosis, and preclinical gene therapy offers a promising avenue for treatment. Key take-home: Biallelic ACADL variants cause a definitive autosomal recessive long chain acyl-CoA dehydrogenase deficiency with clear clinical utility.
Gene–Disease AssociationStrong12 probands across three studies with consistent biochemical deficiency and clinical phenotypes Genetic EvidenceStrong12 unrelated probands demonstrating autosomal recessive biallelic variants and consistent phenotype Functional EvidenceModerateImmunoblot and ETF assays confirm reduced LCAD activity; rAAV rescue in murine model |